1. Berndt E.R. (2002). Pharmaceuticals in U.S. health care: Determinants of quantity and price. The Journal of Economic Perspectives 16: 45–66
2. Berwick D. (2002). We all have AIDS: Case for reducing the cost of HIV drugs to zero. British Medical Journal 324: 214–218
3. California State Office of AIDS. (2004). unpublished report on state expenditures by drug class.
4. Centers for Disease Control and Prevention (CDC). (2005). HIV/AIDS Surveillance Report 2005 (Vol. 17). Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Accessed March 8, 2007 at: http://www.cdc.gov/hiv/topics/surveillance/resources/reports/2005report/default.htm.
5. Clinton Foundation. (2006). Agreements with Nine Companies Will Lower Prices of HIV Diagnosis and Two HIV/AIDS Medicines by 30–50 Percent for 50 Countries. Clinton Foundation Press Release dated January 12, 2006. New York, NY: Clinton Foundation. Available at www.clintonfoundation.org/011206-nr-cf-hs-ai-isr-ind-chn-zaf. Accessed 24 March 2006.